James Francis Demarest | Scholars@Duke

James Francis Demarest
Adjunct Assistant Professor in the Department of Immunology

I have >30 years of experience in the pre-clinical, clinical, and translational research space. Twenty-three of those years are in the pharma R&D context where I also gained experience in diagnostics, product commercialization and life-cycle management, interactions with Regulatory Authorities, Key Opinion Leaders (globally), and establishment/maintenance of public-private partnerships. My career trajectory took me from NIH (Dr. Anthony Fauci’s laboratory), to Duke University, to GlaxoWellcome/GSK, ViiV Healthcare, AbbVie Immunology and consultancies. I was a founding member of the scientific and medical organization at ViiV Healthcare (launched in Nov 2009; www.viivhealthcare.com ) and contributed significantly to shaping its evolving strategy and associated success. I know from firsthand experience the technical and business aspects of building a successful company delivering medicines that meet unmet medical needs. Through my involvement with establishment/launch of collaborations via public-private partnerships and/or business development, I understand what pharma companies expect from partnerships with biotech and/or academia. I have also worked closely with the medical affairs and commercial/marketing organizations on numerous international, regional, and local market projects/campaigns. I bring this breadth of experience to advance innovative approaches for R&D.

The following highlights my general skill set and experience:

R&D Innovation:

- Led and supported research programs, translational research teams, and impact(ed) the business strategy for building a forward-looking R&D pipeline; small molecule, biologic, and vaccine platforms

- Co-developed governance processes to safely expedite compound progression from discovery through clinical development

- Accountable for virology data packages included in 4 successful approvals and global launches (TIVICAY, TRIUMEQ, JULUCA, and DOVATO) and updates to inflammatory bowel disease indications for Humira

- Applying expertise to advancing preventative and therapeutic approaches for SARS-CoV-2 infection and antiviral medical countermeasures

Business Development:

- Subject matter expert for in-licensing review and advisory role informing business development strategy for pre-clinical and clinical R&D platforms/assets and diagnostics

- Member of Integration teams post deal closure

- Advisor for academic-based biotech and entrepreneurial start-ups

Strategic Partnerships:

- Defined and launched multi-year/multi-million-dollar global research collaborations with key academic institutions, including integrated analyses of laboratory generated data with longitudinal patient clinical data

- Initiated, led, or supported in vitro, pre-clinical, and clinical phase global research studies

Commercialization:

- Scientific lead or advisor for commercial/marketing and medical affairs efforts associated with product launches and life cycle management

Diagnostics:

- Directed diagnostic collaborations associated with investigative agents or marketed products

- Provided technical advice for assays and algorithms used in clinical care across diverse geographic regions

Regulatory:

- Written and face-to-face interactions with regulatory authorities pre- and post-market authorization

Scientific Communication:

- Explaining disease area science and medicine mechanisms of action to a broad spectrum of audiences, ranging from key opinion leaders to clinicians/scientists to patient advocates to the lay public

- Graduate and Medical Student mentoring at Duke University

- Freshman Experience Course co-creator/co-lecturer at High Point University

- UNCW OLLI and Duke OLLI invited lecturer

Current Appointments & Affiliations

Adjunct Assistant Professor in the Department of Immunology, Integrative Immunobiology, Basic Science Departments 2000

Contact Information

2212 Meadowcreek Drive, Durham, NC 27705
Duke Box 3010, Durham, NC 27710
jfdem@duke.edu (919) 946-0195

Background
Education, Training, & Certifications
- Ph.D., The George Washington University 1996
Expertise
Subject Headings
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Taylor, Ray, Richard Bowen, James F. Demarest, Michael DeSpirito, Airn Hartwig, Helle Bielefeldt-Ohmann, Dennis M. Walling, Amanda Mathis, and Yarlagadda S. Babu. “Activity of Galidesivir in a Hamster Model of SARS-CoV-2.” Viruses 14, no. 1 (December 21, 2021). https://doi.org/10.3390/v14010008.
    Full Text Open Access Copy Link to Item
  - Julander, Justin G., James F. Demarest, Ray Taylor, Brian B. Gowen, Dennis M. Walling, Amanda Mathis, and Y. S. Babu. “An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.” Antiviral Res 195 (November 2021): 105180. https://doi.org/10.1016/j.antiviral.2021.105180.
    Full Text Open Access Copy Link to Item
  - Boffito, Marta, Laura Waters, Pedro Cahn, Roger Paredes, Justin Koteff, Jean Van Wyk, Tia Vincent, James Demarest, Kimberly Adkison, and Romina Quercia. “Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.” Aids Research and Human Retroviruses 36, no. 1 (January 1, 2020): 13–18. https://doi.org/10.1089/aid.2019.0171.
    Full Text
  - Vannappagari, Vani, Leigh Ragone, Cassidy Henegar, Jean van Wyk, Dannae Brown, James Demarest, Romina Quercia, et al. “Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review.” Antiviral Therapy 24, no. 6 (August 2019): 393–404. https://doi.org/10.3851/imp3331.
    Full Text
  - Heera, Jayvant, Srinivas R. Valluri, Charles Craig, Annie Fang, Neal Thomas, Ralph D. Meyer, Marilyn E. Lewis, Elna van der Ryst, and James Demarest. “First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.” The New Microbiologica 42, no. 2 (April 29, 2019): 101–7.
    Open Access Copy
  - Demarest, James, Mark Underwood, Marty St. Clair, David Dorey, Dannae Brown, and Andrew Zolopa. “Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.” Aids Research and Human Retroviruses 34, no. 4 (April 2018): 343–46. https://doi.org/10.1089/aid.2017.0184.
    Full Text Open Access Copy
  - Ryst, Elna van der, Jayvant Heera, James Demarest, and Charles Knirsch. “Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.” Annals of the New York Academy of Sciences 1346, no. 1 (June 2015): 7–17. https://doi.org/10.1111/nyas.12777.
    Full Text Open Access Copy
  - Cashin, Kieran, Lachlan R. Gray, Katherine L. Harvey, Danielle Perez-Bercoff, Guinevere Q. Lee, Jasminka Sterjovski, Michael Roche, et al. “Reliable genotypic tropism tests for the major HIV-1 subtypes.” Sci Rep 5 (February 25, 2015): 8543. https://doi.org/10.1038/srep08543.
    Full Text Open Access Copy Link to Item
  - Heera, Jayvant, Srinivas Valluri, Charles Craig, Annie Fang, Neal Thomas, Ralph Dan Meyer, and James Demarest. “First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.” Journal of the International Aids Society 17 (November 2014): 19519–19519. https://doi.org/10.7448/ias.17.4.19519.
    Full Text
  - Swenson, Luke C., Celia K. S. Chui, Chanson J. Brumme, Dennison Chan, Conan K. Woods, Theresa Mo, Winnie Dong, et al. “Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.” Antimicrob Agents Chemother 57, no. 12 (December 2013): 6122–30. https://doi.org/10.1128/AAC.01534-13.
    Full Text Link to Item
  - Lee, Guinevere Q., P Richard Harrigan, Winnie Dong, Art F. Y. Poon, Jayvant Heera, James Demarest, Alex Rinehart, Doug Chapman, Hernan Valdez, and Simon Portsmouth. “Comparison of Population and 454 “Deep” Sequence Analysis for HIV Type 1 Tropism Versus the Original Trofile Assay in Non-B Subtypes.” Aids Research and Human Retroviruses 29, no. 6 (June 2013): 979–84. https://doi.org/10.1089/aid.2012.0338.
    Full Text Open Access Copy
  - Portsmouth, Simon, Srinivas Rao Valluri, Martin Daumer, Bernard Thiele, Hernan Valdez, Marilyn Lewis, Charles Craig, et al. “Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing viral tropism co receptor usage of HIV-1 for from 200 treatment-naïve HIV patients screened for Study A4001078.” Antiviral Research 97 (2013): 60–65.
    Open Access Copy
  - Pfaff, Jennifer M., Craig B. Wilen, Jessamina E. Harrison, James F. Demarest, Benhur Lee, Robert W. Doms, and John C. Tilton. “HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.” J Virol 84, no. 13 (July 2010): 6505–14. https://doi.org/10.1128/JVI.00374-10.
    Full Text Link to Item
  - Tilton, John C., Heather Amrine-Madsen, John L. Miamidian, Kathryn M. Kitrinos, Jennifer Pfaff, James F. Demarest, Neelanjana Ray, Jerry L. Jeffrey, Celia C. Labranche, and Robert W. Doms. “HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.” Aids Res Hum Retroviruses 26, no. 1 (January 2010): 13–24. https://doi.org/10.1089/aid.2009.0132.
    Full Text Link to Item
  - Demarest, James F., Heather Amrine-Madsen, David M. Irlbeck, Kathryn M. Kitrinos, and Kathryn M. CCR102881 Clinical Study Team. “Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.” Antimicrob Agents Chemother 53, no. 3 (March 2009): 1116–23. https://doi.org/10.1128/AAC.01055-08.
    Full Text Link to Item
  - Kitrinos, Kathryn M., Heather Amrine-Madsen, David M. Irlbeck, J Michael Word, James F. Demarest, and James F. CCR100136 Study Team. “Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.” Antimicrob Agents Chemother 53, no. 3 (March 2009): 1124–31. https://doi.org/10.1128/AAC.01057-08.
    Full Text Link to Item
  - Demarest, James F., Sara S. Sparks, Kathleen Schell, Shiro Shibayama, Charlene B. McDanal, Lei Fang, Kimberly K. Adkison, Anne Shachoy-Clark, and Stephen C. Piscitelli. “In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.” J Clin Pharmacol 48, no. 10 (October 2008): 1179–88. https://doi.org/10.1177/0091270008322178.
    Full Text Link to Item
  - Irlbeck, David M., Heather Amrine-Madsen, Kathryn M. Kitrinos, Celia C. Labranche, and James F. Demarest. “Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.” Aids 22, no. 12 (July 31, 2008): 1425–31. https://doi.org/10.1097/QAD.0b013e32830184ba.
    Full Text Link to Item
  - Karlsson, Annika C., Steven G. Deeks, Jason D. Barbour, Brandon D. Heiken, Sophie R. Younger, Rebecca Hoh, Meghan Lane, et al. “Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.” J Virol 77, no. 12 (June 2003): 6743–52. https://doi.org/10.1128/jvi.77.12.6743-6752.2003.
    Full Text Link to Item
  - Demarest, J. F., N. Jack, F. R. Cleghorn, M. L. Greenberg, T. L. Hoffman, J. S. Ottinger, L. Fantry, et al. “Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression.” Aids Res Hum Retroviruses 17, no. 14 (September 20, 2001): 1333–44. https://doi.org/10.1089/08892220152596597.
    Full Text Link to Item
  - Soudeyns, H., G. Campi, G. P. Rizzardi, C. Lenge, J. F. Demarest, G. Tambussi, A. Lazzarin, et al. “Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality.” Blood 95, no. 5 (March 1, 2000): 1743–51.
    Link to Item
  - Haynes, B. F., L. P. Hale, K. J. Weinhold, D. D. Patel, H. X. Liao, P. B. Bressler, D. M. Jones, et al. “Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection.” J Clin Invest 103, no. 4 (February 1999): 453–60. https://doi.org/10.1172/JCI5201.
    Full Text Link to Item
  - Pantaleo, G., H. Soudeyns, J. F. Demarest, M. Vaccarezza, C. Graziosi, S. Paolucci, M. B. Daucher, et al. “Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection.” Eur J Immunol 27, no. 12 (December 1997): 3166–73. https://doi.org/10.1002/eji.1830271213.
    Full Text Link to Item
  - Pantaleo, G., H. Soudeyns, J. F. Demarest, M. Vaccarezza, C. Graziosi, S. Paolucci, M. Daucher, et al. “Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection.” Proc Natl Acad Sci U S A 94, no. 18 (September 2, 1997): 9848–53. https://doi.org/10.1073/pnas.94.18.9848.
    Full Text Link to Item
  - Pantaleo, G., J. F. Demarest, T. Schacker, M. Vaccarezza, O. J. Cohen, M. Daucher, C. Graziosi, et al. “The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia.” Proc Natl Acad Sci U S A 94, no. 1 (January 7, 1997): 254–58. https://doi.org/10.1073/pnas.94.1.254.
    Full Text Link to Item
  - Graziosi, C., K. R. Gantt, M. Vaccarezza, J. F. Demarest, M. Daucher, M. S. Saag, G. M. Shaw, et al. “Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection.” Proc Natl Acad Sci U S A 93, no. 9 (April 30, 1996): 4386–91. https://doi.org/10.1073/pnas.93.9.4386.
    Full Text Link to Item
  - Demarest, J. F., and G. Pantaleo. “Analysis of the immunologic events during the primary immune response to HIV infection.” Medecine Biologie Environnement 23, no. 2 (December 1, 1995): 165–70.
  - Koenig, S., A. J. Conley, Y. A. Brewah, G. M. Jones, S. Leath, L. J. Boots, V. Davey, G. Pantaleo, J. F. Demarest, and C. Carter. “Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.” Nat Med 1, no. 4 (April 1995): 330–36. https://doi.org/10.1038/nm0495-330.
    Full Text Link to Item
  - Pantaleo, G., S. Menzo, M. Vaccarezza, C. Graziosi, O. J. Cohen, J. F. Demarest, D. Montefiori, J. M. Orenstein, C. Fox, and L. K. Schrager. “Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.” N Engl J Med 332, no. 4 (January 26, 1995): 209–16. https://doi.org/10.1056/NEJM199501263320402.
    Full Text Link to Item
  - Pantaleo, G., J. F. Demarest, M. Vaccarezza, C. Graziosi, G. P. Bansal, S. Koenig, and A. S. Fauci. “Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission.” Eur J Immunol 25, no. 1 (January 1995): 226–31. https://doi.org/10.1002/eji.1830250137.
    Full Text Link to Item
  - Poggi, A., J. F. Demarest, P. Costa, R. Biassoni, N. Pella, G. Pantaleo, M. C. Mingari, and L. Moretta. “Expression of a wide T cell receptor V beta repertoire in human T lymphocytes derived in vitro from embryonic liver cell precursors.” Eur J Immunol 24, no. 9 (September 1994): 2258–61. https://doi.org/10.1002/eji.1830240949.
    Full Text Link to Item
  - Pantaleo, G., J. F. Demarest, H. Soudeyns, C. Graziosi, F. Denis, J. W. Adelsberger, P. Borrow, M. S. Saag, G. M. Shaw, and R. P. Sekaly. “Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV.” Nature 370, no. 6489 (August 11, 1994): 463–67. https://doi.org/10.1038/370463a0.
    Full Text Link to Item
  - Pantaleo, G., C. Graziosi, J. F. Demarest, O. J. Cohen, M. Vaccarezza, K. Gantt, C. Muro-Cacho, and A. S. Fauci. “Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection.” Immunol Rev 140 (August 1994): 105–30. https://doi.org/10.1111/j.1600-065x.1994.tb00867.x.
    Full Text Link to Item
  - Graziosi, C., G. Pantaleo, K. R. Gantt, J. P. Fortin, J. F. Demarest, O. J. Cohen, R. P. Sékaly, and A. S. Fauci. “Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals.” Science 265, no. 5169 (July 8, 1994): 248–52. https://doi.org/10.1126/science.8023143.
    Full Text Link to Item
  - Rebai, N., G. Pantaleo, J. F. Demarest, C. Ciurli, H. Soudeyns, J. W. Adelsberger, M. Vaccarezza, R. E. Walker, R. P. Sekaly, and A. S. Fauci. “Analysis of the T-cell receptor beta-chain variable-region (V beta) repertoire in monozygotic twins discordant for human immunodeficiency virus: evidence for perturbations of specific V beta segments in CD4+ T cells of the virus-positive twins.” Proc Natl Acad Sci U S A 91, no. 4 (February 15, 1994): 1529–33. https://doi.org/10.1073/pnas.91.4.1529.
    Full Text Link to Item
  - Graziosi, C., G. Pantaleo, J. F. Demarest, O. J. Cohen, M. Vaccarezza, L. Butini, M. Montroni, and A. S. Fauci. “HIV-1 infection in the lymphoid organs.” Aids 7 Suppl 2 (November 1993): S53–58. https://doi.org/10.1097/00002030-199311002-00012.
    Full Text Link to Item
  - Graziosi, C., G. Pantaleo, L. Butini, J. F. Demarest, M. S. Saag, G. M. Shaw, and A. S. Fauci. “Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection.” Proc Natl Acad Sci U S A 90, no. 14 (July 15, 1993): 6405–9. https://doi.org/10.1073/pnas.90.14.6405.
    Full Text Link to Item
  - Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. “HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.” Nature 362, no. 6418 (March 25, 1993): 355–58. https://doi.org/10.1038/362355a0.
    Full Text Link to Item
- Other Articles
  - Haynes, B. F., L. P. Hale, K. J. Weinhold, D. D. Patel, H. X. Liao, P. B. Bressler, D. M. Jones, et al. “Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection.” J Clin Invest, March 15, 1999. https://doi.org/10.1172/jci5201e1.
    Full Text Link to Item
- Conference Papers
  - Kitrinos, K. M., D. M. Irlbeck, C. C. LaBranche, H. A. Madsen, and J. F. Demarest. “Virological characterization of treatment naive subjects failing an aplaviroc-based regimen with either lamivudine/zidovudine or lopinavir/ritonavir.” In Antiviral Therapy, 11:S26–S26. INT MEDICAL PRESS LTD, 2006.
    Link to Item
  - Demarest, James F. “Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5.” In Retrovirology, Vol. 2. Springer Science and Business Media LLC, 2005. https://doi.org/10.1186/1742-4690-2-s1-s13.
    Full Text
  - LaBranche, C. C., D. Davison, R. G. Ferris, G. W. Koszalka, J. F. Demarest, L. R. Boone, and M. L. Greenberg. “Studies with 873140, a novel CCR5 antagonist, demonstrate synergy with enfuvirtide and potent inhibition of enfuvirtide-resistant R5-tropic HIV-1.” In Antiviral Therapy, 10:S73–S73. INT MEDICAL PRESS LTD, 2005.
    Link to Item
  - LaBranche, C. C., D. Davison, R. G. Ferris, G. W. Koszalka, J. F. Demarest, L. R. Boone, and M. L. Greenberg. “Studies with 873140, a novel CCR5 antagonist, demonstrate synergy with enfuvirtide and potent inhibition of enfuvirtide-resistant R5-tropic HIV-1.” In Antiviral Therapy, 10:S73–S73, 2005.
    Link to Item
  - Demarest, J. F., S. Kadereit, S. Brenner-Jones, S. Langdon, M. A. Kelly, J. Mathieson, R. Miller, et al. “V beta repertoire of T lymphocytes emerging in adults after unrelated umbilical cord blood (UCB) allogeneic transplantation.” In Blood, 96:788A-788A. AMER SOC HEMATOLOGY, 2000.
    Link to Item
  - Demarest, J. F., J. Kurtzberg, M. J. Laughlin, S. Kadereit, S. Brenner-Jones, M. Iacobucci, K. McKinnon, H. Zakem-Cloud, and K. J. Weinhold. “V beta repertoire of T lymphocytes emerging after unrelated umbilical cord blood (UCB) transplantation.” In Faseb Journal, 13:A644–A644. FEDERATION AMER SOC EXP BIOL, 1999.
    Link to Item
  - Demarest, J. F., S. B. Jones, G. Ferrari, C. J. Johnson, M. Greenberg, T. O. O’Brien, W. Blattner, et al. “Natural history of HIV-specific CTL activity during acute HIV infection: envelope CTL impact subsequent plasma viremia.” In Faseb Journal, 13:A294–A294. WILEY, 1999.
    Link to Item
  - Demarest, J. F., M. J. Laughlin, S. Kadereit, S. Brenner-Jones, M. Iacobucci, K. McKinnon, H. Zakem-Cloud, and K. Weinhold. “V beta repertoire of T lymphocytes emerging after unrelated umbilical cord blood (UCB) transplantation.” In Blood, 92:291B-291B. W B SAUNDERS CO, 1998.
    Link to Item
  - PANTALEO, G., J. F. DEMAREST, M. VACCAREZZA, M. DAUCHER, C. GRAZIOSI, O. C. COHEN, S. M. SCHNITTMANN, et al. “PRIMARY IMMUNE-RESPONSE TO HIV-INFECTION.” In Aids Research and Human Retroviruses, 11:S149–S149. MARY ANN LIEBERT INC PUBL, 1995.
    Link to Item
  - DEMAREST, J. F., G. PANTALEO, S. ZOLLAPAZNER, G. BANSAL, S. KOENIG, and A. S. FAUCI. “ANTI-V3 ANTIBODIES FAIL TO INHIBIT CELL-TO-CELL TRANSMISSION OF HIV-1.” In Journal of Immunology, 150:A317–A317. AMER ASSOC IMMUNOLOGISTS, 1993.
    Link to Item
  - PANTALEO, G., C. GRAZIOSI, J. F. DEMAREST, L. BUTINI, O. J. COHEN, and A. S. FAUCI. “HIV-INFECTION IS ACTIVE AND PROGRESSIVE DURING THE PROLONGED PERIOD OF CLINICAL LATENCY.” In Journal of Immunology, 150:A243–A243. AMER ASSOC IMMUNOLOGISTS, 1993.
    Link to Item
  - PANTALEO, G., C. GRAZIOSI, J. F. DEMAREST, L. BUTINI, O. J. COHEN, and A. S. FAUCI. “EVIDENCE FOR ACTIVE HIV-INFECTION IN LYMPHOID-TISSUE DURING THE PROLONGED PERIOD OF CLINICAL LATENCY.” In Clinical Research, 41:A259–A259. SLACK INC, 1993.
    Link to Item
  - GRAZIOSI, C., G. PANTALEO, J. F. DEMAREST, M. S. SAAG, G. M. SHAW, and A. S. FAUCI. “ANALYSIS OF HIV PROVIRAL BURDEN AND VIRAL EXPRESSION DURING PRIMARY HIV-INFECTION.” In Journal of Cellular Biochemistry, 2–2. WILEY-LISS, 1993.
    Link to Item
Scholarly, Clinical, & Service Activities
Presentations & Appearances
- Advancing the Treatment of HIV/AIDS Until There is a Cure.. TEDx Elon University: Innovation into Practice. Elon University. February 22, 2014 2014

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Subject Headings

Selected Publications

Academic Articles

Other Articles

Conference Papers

Presentations & Appearances